< previous page | page_58 | next page >
Page 58
| Impairment of memory and ability to concentrate. |
| Diminished intellectual capacity and alertness as a result of insufficient circulation. |
| Anxiety, depression, neurological disorders. |
| Dementia, Alzeimer's disease. |
| Complications of stroke and skull injuries. |
| Diminished sight and hearing ability due to vascular insufficiency. |
| Intermittent claudication as a result of arterial obstruction. |
| A sensitivity to cold and pallor in the toes due to peripheral circulatory insufficiency. |
| Raynaud's disease. |
| Cerebral, vascular and nutritional insufficiency. |
| Hormonal and neural-based disorders as well as angiopathic trophic disorders. |
| Arterial circulatory disturbances due to aging, diabetes and nicotine abuse. |
| Sclerosis of cerebral arteries with and without mental manifestations. |
| Arteriosclerotic angiopathy of lower limbs. |
| Diabetic tissue damage with danger of gangrene. |
| Chronic arterial obliteration. |
| Circulatory disorders of the skin. |
| Preparations and dosage: Gingko is becoming available in a number of different forms. The daily dose used in most studies was 27 mg of gingko flavone glycosides which corresponds to 6 to 12 g of leaf, depending on the quality of the leaf. Tablets or tinctures are usually standardized to contain 22.5 flavone glycosides and hence is highly concentrated compared to the original leaf. In the case of standardized liquid forms the dose is usually 1/4 tsp. 3 times a day. |
< previous page | page_58 | next page >

If you like this book, buy it!